Inflammation and oxidative stress in CKD and dialysis patients

Ebert, T., Neytchev, O. , Witasp, A., Kublickiene, K., Stenvinkel, P. and Shiels, P. (2021) Inflammation and oxidative stress in CKD and dialysis patients. Antioxidants and Redox Signaling, 35(17), pp. 1426-1448. (doi: 10.1089/ars.2020.8184) (PMID:34006115)

[img] Text
242796.pdf - Accepted Version



Significance: Chronic kidney disease (CKD) can be regarded as a burden of lifestyle disease that shares common underpinning features and risk factors with the ageing process; a complex constituted by several adverse components, including chronic inflammation, oxidative stress, early vascular ageing and cellular senescence. Recent Advances: A systemic approach to tackle CKD, based on mitigating the associated inflammatory, cell stress and damage processes, has the potential to attenuate the effects of CKD, but also pre-empts the development and progression of associated morbidities. In effect, this will enhance health span and compress the period of morbidity. Pharmacological, nutritional and potentially lifestyle-based interventions are promising therapeutic avenues to achieve such a goal. Critical Issues: In the present review, currents concepts of inflammation and oxidative damage as key pathomechanisms in CKD are addressed. In particular, potential beneficial but also adverse effects of different systemic interventions in patients with CKD are discussed. Future Directions: Senotherapeutics, the NRF2–KEAP1 signaling pathway, the endocrine klotho axis, inhibitors of the sodium–glucose cotransporter 2 (SGLT2), and live bio-therapeutics have the potential to reduce the burden of CKD and improve quality of life, as well as morbidity and mortality, in this fragile high-risk patient group.

Item Type:Articles
Additional Information:TE was supported by a Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden, a Karolinska Institutet Research Foundation grant, as well as by the EFSD Mentorship Programme supported by AstraZeneca. AW, KK, PS, and TE were further supported by Njurfonden (Swedish Kidney Foundation). PS was supported by the Swedish Heart and Lung Foundation (No 20160384), as well as the Strategic Research Programme in Diabetes at Karolinska Institutet (Swedish Research Council grant No 2009-1068). KK received other grants from the Swedish Research Council (No 2018–00932). PGS is supported by awards from 4D Pharma and Constant Pharma.
Glasgow Author(s) Enlighten ID:Shiels, Professor Paul and Neytchev, Ognian
Authors: Ebert, T., Neytchev, O., Witasp, A., Kublickiene, K., Stenvinkel, P., and Shiels, P.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Antioxidants and Redox Signaling
Publisher:Mary Ann Liebert Inc
ISSN (Online):1557-7716
Published Online:18 May 2021
Copyright Holders:Copyright © 2021 Mary Ann Liebert, Inc.
First Published:First published in Antioxidants and Redox Signaling 35(17):1426-1448
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record